Table Of Content

Author Index Vol. 57, 1999 (B) = Book Review Aikou, T. 29, 131 Del Tacca, M. 195 Horie, Y. 23 Kuroshima, K. 131 Alexopoulos, G. 127 De Stefano, A. 55 Horikoshi, N. 202 Kusaka, Y. 106 Allegrini,G. 195 Didier, F. 297 Hoshino, H. 143 Kusano, N. 42 Anagnostopoulos, A. 127 Dimopoulos, M.A. 127 Hoshino, U. 23 Kuss, I. 265 Antonuzzo, A. 195 Dipple, A. 258 Hsu, H.-C. 149 Arai, Y. 216 Di Re, F. 115 Laperriere, N. 224 Aravantinos, G. | Drapkin, R. 303 lida, A. 106 Lee, C.-C. 149 Ariyoshi, Y. 216 Ikeda, E. 63 Lee, K. 287 Atahan, L. 83 Eckel, F. 269 Ikeguchi, M. 77, 164 Lencioni, M. 195 Autier, P. 297 Emmons, R. Imamura, M. 311 Lersch, C. 269 Espana, P. 17 Inaji, H. 121 Levebvre, K. 287 Baba, M. 29, 131 Inoue, K. 318 Levy, W. 287 Bai, F. 318 Falcone, A. Ishihara,S . 143 Liang, J.-T. 149 Bailey, H. 88 (B) Falkson, C.I. 232 Itami, A. 311 Lim, H.-Y. 236 BakoyiannisC,h . | Falkson, G. 2: Itoh, K. 216 Lin, H.-L. 36 Ballen, K.K. 287 Farnetani, M. 55 Lin, J.-T. 149 Barolo, J.L. 303 Feng, G.-K. 36 Jahnke, K. 99 Lowry, P. 287 Bauernhofer, Th. 265 Ferrandina, G. 211 Japanese Hepatic Arterial Infu- Lundin, J 70, 281 Becker, P. 287 Fiehn, W. 306 sion Study Group 216 Lundin, M 70, 281 Benedetti Panici, P. 211 Fonzo, D. 297 Joensuu, H. 281 Blower, P.R. 303 Forni, M. 10 McGarry, R.C. 293 Boguslawsky, K. von 70 Foti, E. 211 Kadomatsu, K. 25 Maeda, N. 23 Bohm,S . 115 Fountzilas,G . | Kaibara, N. 77, Maehara, Y. 202 Bokkel Huinink, W.W. ten 10 Franssila, K. 242 Kalofonos, Ch. Maeta, M. 77, 164 Bonilla, F. 173 Fueki, N. 143 Kars, A. 83 Makimoto, T. 143 Breasciani,G . 115 Fukusato, T. 15 Kasparek, A.K. Mancuso, S. 211 Brédart, A. 297 Furuya, T. 63 Kasugai, T. 121 Marrelli, D. 55 Bridgewater, J.A. 89 Katano, K. 77 Martini, C. 115 Brunetti, I. 195 Garcia, J.M. 173 Katayama, K. 106 Martucci, R. 211 Burg, M.E.L. van der 10 Garosi, L. 55 Kato, S. 23 Masi, G. 195 Burke, H.B. 281 Gervais-Fagnou, D.D. 224 Kawasaki, H. 23 Matsushita, Y. 29 Gika, D. 127 Kawasaki, M. 318 Messano, A. 55 Caraceni, A. 115 Girouard,C . 224 Kawate, S. 157 Min, H.-Q. 36 Carbone, P.P. 86 (B), 87 (B), Goldhirsch, A. 297 Khan, H. 330 Minato, K. 143 176 (B), 177 (B), 178 (B), Gomendio, B. 173 Khan, Q.A. 258 Mitachi, Y. 202 341 (B), 342 (B) Goss, P.E. 224 Kijima, F. 29 Mitsibounas, D. 127 Carpelan-Holmstrém, M. 70 Grill, H.-J. 324 Kim, H.C. 236 Mori, M. 143 Chang, K.-J. 149 Grosso, I. 115 Kim, H.S. 236 Morishita, Y. 157 Chen, J.-C. 149 Kiyohara, C. 318 Moriya, Y. 276 Cheng, A.-L. 149 Haglund, C. 70 Kobierska, A. 10 Motomura, K. 121 Cheng, Y.-M. 149 Hahka-Kemppinen, M. 242 Koda, M. 23 Mueller, J. 29 Chillar, R. 330 Halikia, A. | Kodaira, S. 138 Muhonen, T. 242 Cho, M. 253 Han, W.S. 236 Kohler, T. 324 Muramatsu,T. 253 Choi, J.-H. 236 Hara, N. 318 Kondo, A. 77 Murawaki, Y. 23 Chuman, Y. 29 Haraguchi, Y. 29 Konishi, N. 253 Collan,Y. 242 Hernberg, M. 242 Kosmidis, P. | Nagumo, S. 121 Conte, P. 195 Hiasa, Y. 253 Kostis, E. 127 Nakagawara,G . 106 Cor, A. 17 Hirao, Y. 253 Kotz, R. 265 Nakamura, K. 216 Costa, A. 297 Hirohashi,S . 276 Koyama, H. 121 Nakamura,M . 253 Hirose, K. 106 Kreienberg, R. 324 Nakanishi, Y. 276, 318 Danesi,R . 195 Hofmann, W.J. 306 Kuang, Z.-J. 36 Nakaoka, S. 253 Datta, G. 330 Hokita, S. 131 Kumada, T. 216 Nam, D.K. 236 1999 S. Karger AG, Basel KARGER Fax +41 61 306 12 34 E-Mail [email protected] Accessible online at www. karger.com www. karger.com/journals/ocl Natsugoe, S. 29, 131 Qian, C.-N. 36 Sdkmensiier, C. 83 Uemura, H. 253 Negri, G. 324 Quesenberry, P. 287 Spatti, G. 115 Umeda, S.-i. 106 Noguchi, S. 121 Stahl, M. 99 Nordling, S. 70 Roberts, P.J. 70 Stamatelopoulos, S. 127 Vadgama, J.V. 330 Robertson, C. 297 Stewart, F.M. 287 Van Triest, B. 179 Ochiai, A. 276 Romanini, M.E. 211 Stickeler, E. 324 VermorkenJ,.B . 10 Oga, A. 42, 63 Roviello, F. 55 Stilgenbauer, F. 306 Visvikis, A. 1 Ohwada, M. 50 Runnebaum, I.B. 324 Stéger, H. 265 Vlaykova, T. 242 Ohwada, S. 157 Rustin, G.J.S. 89 Strother, C.M. 176 (B) Vogl, F.D. 324 Oka, A. 77 Stiiben, G. 99 Volkmann, M. 306 Oka, S. 77 S-1 Gastrointestinal Cancer Stuschke, M. 99 Vousden, K.H. 258 Okita, K. 42 Study Group 202 Sugimachi, K. 202 Okita, S. 42 Sack, H. 99 Sunaga, N. 143 Walz, M.K. 99 Oldenburg, A.R. 99 Sader, R. 269 Suou, T. 23 Wang, L.-G. 36 Oriana, S. 115 Saga, Y. 50 Suzuki, M. 50 Wang, S.-M. 149 Osaki, S.-i. 318 Saito, H. 77 Watanabe, G. 311 Otto, G. 306 Saito, R. 143 Taguchi, T. 202 Watanabe, S. 143 Sakata, Y. 202 Tajima, K. 216 Watanuki, A. 157 Papadimitriou,C . 127 Samonigg, H. 265 Takanami, I. 138 Weyermann, M. 324 Papadimitris, C. 127 Sasaki, K. 42, 63 Takano, K. 318 Wilke, H. 99 Papamichael, C. 127 Sato, I. 50 Takao, S. 131 Wu, M.-S. 149 Paschalidis, M. 269 Sato, T. 63 Takayama, K. 318 Wu, Y. 330 Pectasides, D. 1 Scaffidi, E. 297 Takayasu, Y. 216 Pei, X.-H. 318 Scambia, G. 211 Takeuchi, K. 138 Xiangming,C . 131 Peters, G.J. 179 Schiff, JLH. 306 Talve, L. 242 Pfanner, E. 195 Schulte-Frohlinde, E. 269 Tanabe, G. 131 Yalcin, §. 83, 175 Piccart, M.J. 10 Seeber, S. 99 Tanaka, H. 23 Yamaguchi, A. 106 Pieber, Th.R. 265 Seemayer,T.A. 293 Testa, U. 211 Yamamoto, T. 23 Pilotti, S. 115 Shigoku, A. 23 Theiss, W. 269 Yamauchi, Y. 276 Pintillie, M. 224 Shim, K.-S. 236 Todoroki, T. 63 Ye, Y.-L. 36 Pinto, E. 55 Shimada, M. 29 Toikkanen, S. 281 Yi, S.Y. 236 Pirovano, C. 115 Shimada, Y. 202, 3!1 Tomé, W. 341 (B) Yoshimura, K. 276 Ploner, F. 265 Shiota, G. 23 Tomie, Y. 23 Yoshinaka, H. 29 Provencio, M. 173 Shiraishi, K. 42 Tsuchiya, S. 143 Putten, E. van der 10 Silva, J.M. 173 Tsujitani, S. 77 Zeilhofer, F. 269 Pylkkanen, L. 281 Skarlos, D. | l'sukagoshi, S. 50 Zunino, F. 115 Pyrhénen, S. 242 Smith, C. 293 Tujitani,S . 164 Oncology Vol. 5 _ 1999 Author Index Subject Index Vol. 57, 1999 EPROM LT: AA, LTE GL RENT IOI PI AIS RAMONE BE African-American women 330 DNA 63 Kip] 311 AGM-1470 36 Doxorubicin 232 Ag-NOR 17 Lavage cytology 121 Angiogenesis 138 Early gastric cancer 131 Leucovorin 195 -— inhibitor 36 - phase II study 202 Liver metastases 216 Antiangiogenic therapy 36 Enzyme-linked immunosorbent assay 236 Lumpectomy cavity 121 Antibioticso,ra l 127 Esophageal cancer 311 Lymph node metastasis 131 Antifolates 179 - tumor 29 Anxiety disorder, generalised 297 Extragonadal germ cell tumours | Malignancy, ovarian 89 Argyrophilic nucleolar organizer regions Malignant seeding 121 157 Fatigue 303 M-CSF 211 Autoantibodies 324 FEM 216 Metastatic melanoma 242 Axial skeleton 265 Flow cytometry 29, 63 - osteosarcoma 265 Fluorescence in situ hybridization 63 Methylation 149 Biliary tract cancers 42 5-Fluorouracil 179, 195 Methylation-specific PCR 149 Bone marrow transplantation 287 — derivative 202 5-Methylchrysene 258 Breast cancer 121, 224, 281, 330 MIB-1 17, 157, 242 Breast-conserving surgery 121 G1 arrest 258 Micrometastasis 276 Gastric cancer 55, 106, 202, 216 Microvessel 164 c-myc amplification 157 — carcinoma 164, 236 Midkine 253 CA 19-9 55 Gastrointestinal carcinoma 195 Mixed mullerian tumour 89 72-4 55 — malignancy 269 MTS1 149 Cancer 63 Genetic aberrations 42 Multivariate regression analysis 106 Carcinosarcoma 29 Germ cell 89 Mutation 306 Case-control study 276 Glutathione 115 a-Catenin 131 — §-transferase-x 318 Nasopharyngeal carcinoma Catheter-related thrombosis 269 Granisetron 303 Neural networks 281 CD31 242 Granulosa cell 89 iNeuroendocrine carcinoma CDKN2 306 Neutropenic fever 127 CDKN2A 149 Hemorrhagic cystitis 287 Non-small cell lung cancer CEA 55 Hepatic arterial infusion 216 Cervical cancer 50 Hepatocellular carcinoma 23, 232, 306 Oesophageal carcinoma 99 - oesophagus 99 High-dose epirubicin 10 Oncology 330 Cervix 293 Hispanic women 330 Ovarian cancer 211, 324 Chemotherapy 318 Hodgkin’s disease(s) 83, 224 — carcinoma 115 Cholestasis 83 Hospital Anxiety and Depression Scale 297 Oxaliplatin 179 Chromosome 63 Hiirthle cell tumour 17 Chronoinfusion 195 Hyperthermic peritoneal perfusion 106 pl6 149 Cisplatin 77, 115, 318 Hypotonic chemotherapy pl6INK4a 149 Clofazimine 232 p21 vce! 258 Colon 63 IAP 211 p27 311 Color-coded duplex sonography 269 IGFBP3 330 p53 131, 157, 164, 258, 318, 324 Colorectal cancer(s) 70, 149, 202, 276 IGF-I 330 PCNA 17 Comparative genomic hybridization IL-6 211 PCR-single strand conformation polymor- 42 Immunohistochemistry 29, 50, 70, 131, phism 306 CyclinD1 311 253, 276 Pedunculated hepatocellular carcinoma Cyclophosphamide 287 Interferon 303 2732 Cytogenetics 63 Interventions, psychosocial, psychiatric 22 97 Performance status 303 Intraperitoneal chemotherapy Peripheral blood stem cells 287 Density 138 Irinotecan 179 — ports 269 Depressive disorder, major 997 Peritoneal carcinomatosis Diagnosis 324 Jaundice, paraneoplastic 83 — metastases 106 1999 S. Karger AG, Basel KARGER Fax +41 61 306 12 34 E-Mail [email protected] Accessible online at www. karger.com www. karger.com/journals/ocl Phase I-II 195 Radiation-induced breast cancer 224 Stromal tumour 89 Platinum-based chemotherapy | Radiochemotherapy 99 Survival 311 Polymerase chain reaction 157 Randomized trial 195 — prediction 281 Port infection 269 Recurrence, local 121 Postmenopausal status 324 Relapsed ovarian carcinoma 10 Thymidylate synthase 50, 179 Prior cisplatin 10 TNP-470 36 Pro-gastrin-releasing peptide 143 S-1 202 Topoisomerase 179 Prognosis 23 Salvage combination chemotherapy 265 Transbronchial biopsy 318 Prognostic factor 50, 311 Serum 236 Transforming growth factor-a 236 Proliferation 242 - levels 211 Tumo(u)r marker(s) 55, 89, 143 Prostate cancer 253 Small cell carcinoma 293 Tumor-associated macrophage 138 Prostatic intraepithelial neoplasia — -— lungcancer 143 Pulmonary adenocarcinoma 138 Spondylectomy, total 265 Vascular endothelial growth factor 164 Stn 70 Vascularity 242 Oncology Vol. 57, 1999 Subject Index